Shots:

• Alexion has exercised its option to acquire all remaining equity in Caelum for CAEL-101 which is currently being evaluated in P-III CARES clinical program that consists of 2 P-III trials in combination with SoC therapy for AL amyloidosis
• Caelum to receive ~$150M as an option exercise fee in addition to ~$350M upon the achievement of regulatory & commercial milestones. The transaction is expected to close on Oct 5- 2021
• CAEL-101 is a mAb- targeted for reducing and eliminating amyloid accumulation in patients with AL. The therapy has received ODD from the both US FDA & EC for the same indication & also received FDA’s FTD while two P-III trials in patients with Mayo stage IIIa & IIIb are ongoing

  | Ref: AstraZeneca | Image: Businesswire